Enjoying the archive? Get new posts in your inbox.
GLP1
+2
Jul 21, 2026
•
4 min read
I Put Twelve GLP-1 Trials on One Page
The evidence that actually holds up in 2026 — weight loss, heart, kidney, muscle, and the myths that should have died already. Free one-page reference inside.
Lipids
+1
Jul 18, 2026
•
2 min read
The PCSK9 Pill Is Here. The Needle Was the Barrier.
The FDA approved the first oral PCSK9 inhibitor — antibody-class LDL-C lowering from a once-daily tablet. Here is what it does, and the one thing it hasn't proven yet.
GLP1
+2
Jul 11, 2026
•
6 min read
SPECIAL EDITION: Nobody Asked.
A new JAMA secret-shopper study bought 45 GLP-1 prescriptions online. Most arrived in a day. Some in under 5 minutes. Almost none asked the questions that keep patients safe. I have watched this happen from the inside, and I know exactly why.
GLP1
+1
Jul 7, 2026
•
3 min read
I Built a Live Index of Every Obesity Drug Trial
The pipeline moves faster than any newsletter can. So I stopped trying to summarize it and built something that updates itself.
GLP1
+2
Jul 4, 2026
•
11 min read
Obesity Medicine Stopped Being a Horse Race
Nine drugs, four receptors, and two new pills into 2026, the field is quietly reorganizing around a better question. Not how much weight. Which disease.
Cancer
+1
Jun 30, 2026
•
7 min read
The Cancer We Vaccinated Away
For five straight years, not one young woman in England has died of cervical cancer. A new Lancet analysis shows what the end of a disease looks like in real time, and why the timing could not be more painful.
GLP1
+1
Jun 27, 2026
•
10 min read
The patient barely lost weight. He got better anyway.
What the newest trial data reveal about GLP-1 medicines, and why "weight loss drug" may be the least interesting thing about them.
GLP1
+2
Jun 23, 2026
•
8 min read
Medicare Will Pay for Wegovy Now. Here's the Catch.
Starting July 1, eligible Medicare patients get Wegovy, Zepbound, or the new pill Foundayo for $50 a month. The program is real. It's transformative. And almost everything you've read about it is slightly wrong.